Skip to main content

Interactions between Exemestane and Menthol topical

1 drug interaction and 2 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Minor drug interactions

Minor:

menthol topical exemestane

Applies to: menthol topical and exemestane

Coadministration with orally administered menthol may decrease plasma concentrations of drugs that are substrates of the CYP450 3A4 and/or CYP450 2C9 isoenzymes. The proposed mechanism is increased clearance due to menthol-mediated induction of CYP450 3A4 and CYP450 2C9. In vivo data suggests that concomitant administration of oral menthol reduced the systemic exposure (AUC) of triazolam (a CYP450 3A4 substrate) by 40%, and phenytoin (a CYP450 2C9 substrate) by 20%. Until further data are available, no specific precautions are recommended.

References (4)
  1. (2024) "Product Information. Advil Targeted Relief (camphor/capsicum/menthol/methyl salicylate topical)." Haleon
  2. Hoshino M (2015) "Effects of menthol on the pharmacokinetics of triazolam and phenytoin." Biol Pharm Bull, 38, p. 454-60
  3. Hoshino M (2014) "Menthol reduces the anticoagulation effect of warfarin by cytochrome p450 2C expression." Eur J Pharm Sci, 56, p. 92-101
  4. (2019) "Product Information. Radian B Muscle Rub (camphor/capsicum/menthol/meth salic top)." Thornton & Ross Ltd

Food/lifestyle interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Disease interactions

2 potential interactions Applies to: 2 conditions, including Vitamin D Deficiency and Osteoporosis.

Osteoporosis

Moderate:

exemestane

Exemestane has a moderate potential interaction with Osteoporosis.

Reductions in bone mineral density (BMD) over time are seen with the use of exemestane. Women with osteoporosis or at risk of osteoporosis should have their BMD formally assessed by densitometry at treatment initiation. Monitoring for BMD loss is recommended, and treatment for it should be started as appropriate.

Vitamin D Deficiency

Moderate:

exemestane

Exemestane has a moderate potential interaction with Vitamin D Deficiency.

Routine assessment of vitamin D levels prior to the start of aromatase inhibitor treatment should be performed, due to the high prevalence of vitamin D deficiency in women with early breast cancer. Women with vitamin D deficiency should receive supplementation.

Report options

Loading...
QR code containing a link to this page

More resources

exemestane

A total of 94 drugs are known to interact with exemestane.

menthol topical

A total of 364 drugs are known to interact with menthol topical.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer